吉西他滨 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "吉西他滨" in Chinese language version.

refsWebsite

Global rank Chinese rank

16nih.gov

4^th place

5^th place

16doi.org

2^nd place

23^rd place

15web.archive.org

1^st place

2drugs.com

399^th place

208^th place

2handle.net

102^nd place

492^nd place

2books.google.com

3^rd place

8^th place

2semanticscholar.org

11^th place

332^nd place

1cancercareontario.ca

low place

1cancer.gov

1,684^th place

696^th place

1fiercebiotech.com

low place

1news-medical.net

8,069^th place

8,814^th place

1medicines.org.uk

3,823^rd place

3,456^th place

1fda.gov

447^th place

581^st place

1macmillan.org.uk

low place

1archive.org

6^th place

4^th place

1soton.ac.uk

6,219^th place

4,671^st place

1europa.eu

68^th place

209^th place

1fiercepharma.com

low place

1missouri.edu

3,342^nd place

5,166^th place

1seekingalpha.com

5,344^th place

7,113^th place

1cancernetwork.com

low place

7,315^th place

archive.org

Rachel Airley. Cancer Chemotherapy. Wiley-Blackwell. 2009. ISBN 978-0-470-09254-5.

books.google.com

Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 511. ISBN 9783527607495.
Wang MH, Alexandre D. Analysis of Cases on Pharmaceutical Patent Infringement in Great China. Iimura T, Wang MH, Voit TJ, Rader RR (编). Law, Politics and Revenue Extraction on Intellectual Property. Cambridge Scholars Publishing. 2015: 119. ISBN 9781443879262. （原始内容存档于2017-09-11）（英语）.

cancer.gov

FDA Approval for Gemcitabine Hydrochloride. National Cancer Institute. 2006-10-05 [2017-04-22]. （原始内容存档于2017-04-05）.

cancercareontario.ca

Drug Formulary/Drugs/ gemcitabine - Provider Monograph. Cancer Care Ontario. [2020-12-06]. （原始内容存档于2019-02-24）.

cancernetwork.com

Pishvaian MJ, Brody JR. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology. March 2017, 31 (3): 159–66, 168. PMID 28299752. （原始内容存档于2017-07-03）.

doi.org

Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, et al. Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Research. December 2020, 184: 104967. PMID 33137361. doi:10.1016/j.antiviral.2020.104967 . hdl:1765/133780 .
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology. June 2017, 12 (3): 309–321. PMID 28353074. S2CID 3833614. doi:10.1007/s11523-017-0486-5.
Plentz RR, Malek NP. Systemic Therapy of Cholangiocarcinoma. Visceral Medicine. December 2016, 32 (6): 427–430. PMC 5290432 . PMID 28229078. doi:10.1159/000453084.
Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology. November 2016, 17 (11): 58. PMID 27658789. S2CID 25477593. doi:10.1007/s11864-016-0432-2.
Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International. July 2017, 92 (1): 37–46. PMID 28318633. doi:10.1016/j.kint.2016.11.029 .
Kasi PM. Thrombotic thrombocytopenic purpura and gemcitabine. Case Reports in Oncology. January 2011, 4 (1): 143–148. PMC 3114619 . PMID 21691573. doi:10.1159/000326801.
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, et al. PharmGKB summary: gemcitabine pathway. Pharmacogenetics and Genomics. November 2014, 24 (11): 564–574. PMC 4189987 . PMID 25162786. doi:10.1097/fpc.0000000000000086.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Annals of Oncology. May 2006, 17 (Suppl 5): v7–12. PMID 16807468. doi:10.1093/annonc/mdj941 .
Fatima, M., Iqbal Ahmed, M. M., Batool, F., Riaz, A., Ali, M., Munch-Petersen, B., & Mutahir, Z. (2019). Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian Journal of Basic Medical Sciences, 19(4), 342-349. https://doi.org/10.17305/bjbms.2019.4136
Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry: A European Journal. 2007, 13 (30): 8507–8515. PMID 17636467. doi:10.1002/chem.200700260.
Brown K, Weymouth-Wilson A, Linclau B. A linear synthesis of gemcitabine. Carbohydrate Research. April 2015, 406: 71–75. PMID 25681996. doi:10.1016/j.carres.2015.01.001 .
Brown K, Dixey M, Weymouth-Wilson A, Linclau B. The synthesis of gemcitabine (PDF). Carbohydrate Research. March 2014, 387: 59–73. PMID 24636495. doi:10.1016/j.carres.2014.01.024.
Dyawanapelly S, Kumar A, Chourasia MK. Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy. Critical Reviews in Therapeutic Drug Carrier Systems. 2017, 34 (1): 63–96. PMID 28322141. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912.
Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomedicine & Pharmacotherapy. April 2017, 88: 635–643. PMID 28142120. doi:10.1016/j.biopha.2017.01.071.
Dubey RD, Saneja A, Gupta PK, Gupta PN. Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. European Journal of Pharmaceutical Sciences. October 2016, 93: 147–162. PMID 27531553. doi:10.1016/j.ejps.2016.08.021.
Krown SE. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Current Opinion in Oncology. September 2011, 23 (5): 463–468. PMC 3465839 . PMID 21681092. doi:10.1097/cco.0b013e328349428d.

drugs.com

Gemcitabine International Brands. Drugs.com. [6 May 2017]. （原始内容存档于2014-05-25）.
Gemcitabine Hydrochloride. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2017-02-02）.

europa.eu

ema.europa.eu

Gemzar. European Medicines Agency. 2008-09-24. （原始内容存档于2017-09-11）（英语）.

fda.gov

accessdata.fda.gov

US formLabel (PDF). FDA. June 2014 [2017-05-06]. （原始内容存档 (PDF)于2017-02-16）. For label updates see FDA index page for NDA 020509 互联网档案馆的存檔，存档日期2017-04-29.

fiercebiotech.com

Myers C. Gemcitabine from Actavis launched on patent expiry in EU markets. FierceBiotech. 2009-03-13. （原始内容存档于2017-09-11）（英语）.

fiercepharma.com

Myers C. Patent for Lilly's cancer drug Gemzar invalidated. FiercePharma. 2009-08-18. （原始内容存档于2017-09-11）（英语）.

handle.net

hdl.handle.net

Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, et al. Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Research. December 2020, 184: 104967. PMID 33137361. doi:10.1016/j.antiviral.2020.104967 . hdl:1765/133780 .
World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.

macmillan.org.uk

Gemcitabine. Macmillan Cancer Support. [2017-05-06]. （原始内容存档于2017-03-25）.

medicines.org.uk

UK label. UK Electronic Medicines Compendium. 2014-06-05 [2017-05-06]. （原始内容存档于2017-07-10）（英语）.

missouri.edu

law.missouri.edu

Holman CM. Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation (PDF). Missouri Law Review. Summer 2011, 76 (3): 645–693 [2017-05-06]. （原始内容 (PDF)存档于2017-09-11）.

news-medical.net

Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection. Hospira via News-Medical.Net. 2010-11-16. （原始内容存档于2015-10-02）（英语）.

nih.gov

ncbi.nlm.nih.gov

Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, et al. Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Research. December 2020, 184: 104967. PMID 33137361. doi:10.1016/j.antiviral.2020.104967 . hdl:1765/133780 .
Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology. June 2017, 12 (3): 309–321. PMID 28353074. S2CID 3833614. doi:10.1007/s11523-017-0486-5.
Plentz RR, Malek NP. Systemic Therapy of Cholangiocarcinoma. Visceral Medicine. December 2016, 32 (6): 427–430. PMC 5290432 . PMID 28229078. doi:10.1159/000453084.
Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology. November 2016, 17 (11): 58. PMID 27658789. S2CID 25477593. doi:10.1007/s11864-016-0432-2.
Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International. July 2017, 92 (1): 37–46. PMID 28318633. doi:10.1016/j.kint.2016.11.029 .
Kasi PM. Thrombotic thrombocytopenic purpura and gemcitabine. Case Reports in Oncology. January 2011, 4 (1): 143–148. PMC 3114619 . PMID 21691573. doi:10.1159/000326801.
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, et al. PharmGKB summary: gemcitabine pathway. Pharmacogenetics and Genomics. November 2014, 24 (11): 564–574. PMC 4189987 . PMID 25162786. doi:10.1097/fpc.0000000000000086.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Annals of Oncology. May 2006, 17 (Suppl 5): v7–12. PMID 16807468. doi:10.1093/annonc/mdj941 .
Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry: A European Journal. 2007, 13 (30): 8507–8515. PMID 17636467. doi:10.1002/chem.200700260.
Brown K, Weymouth-Wilson A, Linclau B. A linear synthesis of gemcitabine. Carbohydrate Research. April 2015, 406: 71–75. PMID 25681996. doi:10.1016/j.carres.2015.01.001 .
Brown K, Dixey M, Weymouth-Wilson A, Linclau B. The synthesis of gemcitabine (PDF). Carbohydrate Research. March 2014, 387: 59–73. PMID 24636495. doi:10.1016/j.carres.2014.01.024.
Dyawanapelly S, Kumar A, Chourasia MK. Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy. Critical Reviews in Therapeutic Drug Carrier Systems. 2017, 34 (1): 63–96. PMID 28322141. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912.
Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomedicine & Pharmacotherapy. April 2017, 88: 635–643. PMID 28142120. doi:10.1016/j.biopha.2017.01.071.
Dubey RD, Saneja A, Gupta PK, Gupta PN. Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. European Journal of Pharmaceutical Sciences. October 2016, 93: 147–162. PMID 27531553. doi:10.1016/j.ejps.2016.08.021.
Pishvaian MJ, Brody JR. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology. March 2017, 31 (3): 159–66, 168. PMID 28299752. （原始内容存档于2017-07-03）.
Krown SE. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Current Opinion in Oncology. September 2011, 23 (5): 463–468. PMC 3465839 . PMID 21681092. doi:10.1097/cco.0b013e328349428d.

seekingalpha.com

Ravicher DB. On the Generic Gemzar Patent Fight. Seeking Alpha. 2010-07-28. （原始内容存档于2012-12-09）.

semanticscholar.org

api.semanticscholar.org

Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology. June 2017, 12 (3): 309–321. PMID 28353074. S2CID 3833614. doi:10.1007/s11523-017-0486-5.
Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology. November 2016, 17 (11): 58. PMID 27658789. S2CID 25477593. doi:10.1007/s11864-016-0432-2.

soton.ac.uk

eprints.soton.ac.uk

Brown K, Dixey M, Weymouth-Wilson A, Linclau B. The synthesis of gemcitabine (PDF). Carbohydrate Research. March 2014, 387: 59–73. PMID 24636495. doi:10.1016/j.carres.2014.01.024.

web.archive.org

Gemcitabine International Brands. Drugs.com. [6 May 2017]. （原始内容存档于2014-05-25）.
Drug Formulary/Drugs/ gemcitabine - Provider Monograph. Cancer Care Ontario. [2020-12-06]. （原始内容存档于2019-02-24）.
Gemcitabine Hydrochloride. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2017-02-02）.
FDA Approval for Gemcitabine Hydrochloride. National Cancer Institute. 2006-10-05 [2017-04-22]. （原始内容存档于2017-04-05）.
Myers C. Gemcitabine from Actavis launched on patent expiry in EU markets. FierceBiotech. 2009-03-13. （原始内容存档于2017-09-11）（英语）.
Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection. Hospira via News-Medical.Net. 2010-11-16. （原始内容存档于2015-10-02）（英语）.
UK label. UK Electronic Medicines Compendium. 2014-06-05 [2017-05-06]. （原始内容存档于2017-07-10）（英语）.
US formLabel (PDF). FDA. June 2014 [2017-05-06]. （原始内容存档 (PDF)于2017-02-16）. For label updates see FDA index page for NDA 020509 互联网档案馆的存檔，存档日期2017-04-29.
Gemcitabine. Macmillan Cancer Support. [2017-05-06]. （原始内容存档于2017-03-25）.
Gemzar. European Medicines Agency. 2008-09-24. （原始内容存档于2017-09-11）（英语）.
Myers C. Patent for Lilly's cancer drug Gemzar invalidated. FiercePharma. 2009-08-18. （原始内容存档于2017-09-11）（英语）.
Holman CM. Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation (PDF). Missouri Law Review. Summer 2011, 76 (3): 645–693 [2017-05-06]. （原始内容 (PDF)存档于2017-09-11）.
Ravicher DB. On the Generic Gemzar Patent Fight. Seeking Alpha. 2010-07-28. （原始内容存档于2012-12-09）.
Wang MH, Alexandre D. Analysis of Cases on Pharmaceutical Patent Infringement in Great China. Iimura T, Wang MH, Voit TJ, Rader RR (编). Law, Politics and Revenue Extraction on Intellectual Property. Cambridge Scholars Publishing. 2015: 119. ISBN 9781443879262. （原始内容存档于2017-09-11）（英语）.
Pishvaian MJ, Brody JR. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology. March 2017, 31 (3): 159–66, 168. PMID 28299752. （原始内容存档于2017-07-03）.